Dr. Alexander Starodub, MD
Claim this profileThe Christ Hospital
Studies Solid Tumors
Studies Lung Cancer
17 reported clinical trials
26 drugs studied
Area of expertise
1Solid Tumors
Stage IV
KRAS positive
HRAS positive
2Lung Cancer
Stage IV
Stage III
HER3 negative
Affiliated Hospitals
Clinical Trials Alexander Starodub, MD is currently running
YL-17231
for Solid Tumors
This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
Recruiting1 award Phase 117 criteria
TUB-040
for Ovarian and Lung Cancers
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for patients. TUB-040 is given IV every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Recruiting1 award Phase 1 & 2
More about Alexander Starodub, MD
Clinical Trial Related3 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Alexander Starodub, MD has experience with
- PD-1 Inhibitor
- LUT014 Gel
- YL-17231
- AMV564
- Docetaxel
- SM08502
Breakdown of trials Alexander Starodub, MD has run
Solid Tumors
Lung Cancer
Breast Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Starodub, MD specialize in?
Alexander Starodub, MD focuses on Solid Tumors and Lung Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are KRAS positive.
Is Alexander Starodub, MD currently recruiting for clinical trials?
Yes, Alexander Starodub, MD is currently recruiting for 4 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Alexander Starodub, MD has studied deeply?
Yes, Alexander Starodub, MD has studied treatments such as PD-1 inhibitor, LUT014 Gel, YL-17231.
What is the best way to schedule an appointment with Alexander Starodub, MD?
Apply for one of the trials that Alexander Starodub, MD is conducting.
What is the office address of Alexander Starodub, MD?
The office of Alexander Starodub, MD is located at: The Christ Hospital, Cincinnati, Ohio 45219 United States. This is the address for their practice at the The Christ Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.